Business Description
argenx SE
ISIN : US04016X1019
Compare
Compare
Traded in other countries / regions
ARGX.USAARGX.Belgium0QW0.UK1AE.GermanyARGX.AustriaA1RG34.BrazilARGX.Mexico IPO Date
2017-05-18Description
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 177.62 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 53.8 | |||||
| Beneish M-Score | 4.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 57.4 | |||||
| 3-Year EBITDA Growth Rate | -38.8 | |||||
| 3-Year EPS without NRI Growth Rate | -42.9 | |||||
| 3-Year Book Growth Rate | 24.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 89.11 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.58 | |||||
| 9-Day RSI | 44.15 | |||||
| 14-Day RSI | 49.36 | |||||
| 6-1 Month Momentum % | 40.65 | |||||
| 12-1 Month Momentum % | 47.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.47 | |||||
| Quick Ratio | 7.84 | |||||
| Cash Ratio | 6.28 | |||||
| Days Inventory | 1043.66 | |||||
| Days Sales Outstanding | 98.67 | |||||
| Days Payable | 1018.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9 | |||||
| Shareholder Yield % | -0.01 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.86 | |||||
| Operating Margin % | -67.47 | |||||
| Net Margin % | -51.16 | |||||
| ROE % | -14.36 | |||||
| ROA % | -12.96 | |||||
| ROIC % | -68.85 | |||||
| ROC (Joel Greenblatt) % | -200.2 | |||||
| ROCE % | -15.84 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 33.29 | |||||
| PB Ratio | 9.59 | |||||
| Price-to-Tangible-Book | 10.27 | |||||
| EV-to-EBIT | -62.83 | |||||
| EV-to-Forward-EBIT | -112.56 | |||||
| EV-to-EBITDA | -62.83 | |||||
| EV-to-Forward-EBITDA | -115.45 | |||||
| EV-to-Revenue | 34.62 | |||||
| EV-to-Forward-Revenue | 17.69 | |||||
| EV-to-FCF | -28.58 | |||||
| Price-to-Net-Current-Asset-Value | 11.64 | |||||
| Price-to-Net-Cash | 16.51 | |||||
| Earnings Yield (Greenblatt) % | -1.59 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARGX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
argenx SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 801.831 | ||
| EPS (TTM) ($) | -7.1 | ||
| Beta | 0.57 | ||
| Volatility % | 32.78 | ||
| 14-Day RSI | 49.36 | ||
| 14-Day ATR ($) | 9.931026 | ||
| 20-Day SMA ($) | 514.6655 | ||
| 12-1 Month Momentum % | 47.75 | ||
| 52-Week Range ($) | 333.07 - 550.76 | ||
| Shares Outstanding (Mil) | 58.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
argenx SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
argenx SE Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
argenx SE Frequently Asked Questions
What is argenx SE(ARGX)'s stock price today?
The current price of ARGX is $483.54. The 52 week high of ARGX is $550.76 and 52 week low is $333.07.
When is next earnings date of argenx SE(ARGX)?
The next earnings date of argenx SE(ARGX) is 2023-10-27.
Does argenx SE(ARGX) pay dividends? If so, how much?
argenx SE(ARGX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers